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Role of MLL-Wild Type in hematopoesis and leukemia 
transformation in MLL-Partial Tandem Duplication mouse models  
Acute Myeloid Leukemia (AML) is a blood cancer arising mostly in older 
adults. MLL-partial tandem duplication (MLL-PTD) is present in 5-7% of 
cytogenetically normal AML patients. FLT3-internal tandem duplication 
(FLT3-ITD) is found in 30-35% of AML patients. A subset of AML patients 
with both FLT3-ITD and MLL-PTD have a poor prognosis.  
Single mutant mice expressing either Mll-PTD or Flt3-ITD independently 
do not develop leukemia; however, a double mutant mouse expressing 
Mll-PTD and Flt3-ITD develops AML with a long latency and mimics 
human AML phenotypically and molecularly1. 
MLL-WT expression is silenced in both human samples2 and mouse 
models3 of MLL-PTD+ AML. Germ-line absence of Mll-WT in Mll-PTD+ 
(MllPTD/-) mice is embryonic lethal4, so an Mll-PTD conditional knockout 
mouse was obtained to generate MllPTD/FLOX;Flt3ITD/WT mice. 
Objective 1: Does Mll-PTD maintain gain-of-function in the absence of 
Mll-WT? 
Objective 2: Is Mll-WT a tumor suppressor in an Mll-PTD+ AML murine 
model?? 
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Mll-PTD;Flt3-ITD cooperate to 
induce fatal acute leukemia 
MllPTD/WT;Flt3ITD/WT mice with AML 
develop splenomegaly 
MllPTD/WT:Flt3ITD/WT murine acute 
leukemia is similar to human AML 
The floxed (Mll-FLOX) allele is completely deleted, producing Mll-ΔN in 
hematopoietic tissues after induction of Cre recombinase.   
Cre induction deletes Mll-FLOX to 
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Future Directions to analyze Mll-
WT in acute leukemia model 
1.  Evaluate whether loss of Mll-WT (hypothesized to function as a tumor 
suppressor in Mll-PTD+ AML) decreases latency of leukemogenesis in 
an Mll-PTD;Flt3-ITD mouse model of AML .   
2.   Evaluate expression of oncogenic HoxA9 and Meis1 in MllPTD/
FLOX;Flt3ITD/ITD mouse model pre- and post- conditional knockout. 
3.   Monitor disease progression by flow cytometry based 
immunophenotyping. 
Spleens of mice at time of harvest (80 wks). 
RT-PCR data demonstrates silencing 
of Mll-WT expression in leukemic 
MllPTD/WT:Flt3ITD/WT mice.  
 
Survival curve of single knock-in and WT control mice in 
comparison to the heterozygous double mutant mice. 
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Objective 1: Does Mll-PTD 
function without Mll-WT? 
Objective 2: Is Mll-WT a tumor 
supressor in Mll-PTD+ AML? 
MllPTD/ΔN, MllPTD/FLOX, and MllFLOX/FLOX mice do not succumb to 
BM failure after deletion of Mll-floxed allele.  
 
Experimental design of to test whether Mll-WT affects 
leukemia transformation in Mll-PTD+ murine model. 
Experimental design of conditional knockout of Mll-WT floxed allele 
(Mll-FLOX). 
Summary         
1.  Mll-PTD;Flt3-ITD mice develop a transplantable AML that is 
phenotypically and molecularly similar to human AML. 
2.  MllPTD/ΔN mice maintain normal hematopoiesis survive, but MllΔN/ΔN 
mice succumb to bone marrow failure soon after induction. 
3.  Mll-PTD appears to act as a gain-of-function mutation based on 
expression levels of the downstream Mll targets HoxA9 and Meis1.   
4.  Breeding of  MllPTD/FLOX;Flt3ITD/WT with and without Cre mice is in 
progress to help evaluate the effect of Mll-WT on AML 
transformation. 
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Mll-PTD acts as a gain-of-function 
mutation in the absence of Mll-WT 
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